摘要:Since the inception of Medicare Part D in 2006, mergers and acquisitions (M&A) and regulatory changes have led to increased concentration and reduced plan variety in the standalone prescription drug plan (PDP) portion of the market. We examine how this industry consolidation affects Medicare beneficiaries’ enrollment in PDPs and their out-of-pocket (OOP) drug expenditures using individual-level data from the 2006-2018 waves of the Health and Retirement Study (HRS) merged with PDP market-level characteristics. Overall, we find that lower plan variety in the PDP market decreases the likelihood that elderly individuals enroll in PDPs, and higher PDP market concentration increases OOP drug expenditures. Our main results are robust to considering possible effects of unobserved individual-level heterogeneity, region-specific time trends, and entry/exit of insurers, as well as to the use of an alternative identification scheme based on a quasi-experimental design. Further, we find that younger, more advantaged, and healthier individuals respond differently to industry consolidation compared to their older, less advantaged, and sicker counterparts. The former groups are more likely to adjust their PDP enrollment in response to reduced PDP variety and have higher OOP drug expenditures in response to increased PDP market concentration compared to the latter groups. Finally, we find that not only do lower PDP variety and greater PDP market concentration directly affect PDP enrollment and OOP drug expenditures, but these changes also affect Medicare beneficiaries indirectly through impacting PDP characteristics.
自2006年Medicare Part D成立以来,合并和收购(M&A)以及监管变化导致了市场独立处方药计划(PDP)部分的集中度增加和计划种类减少。我们利用2006-2018年健康与退休研究(HRS)的个体级数据,并结合PDP市场层面的特征,研究了这种行业整合如何影响医疗保险受益人参与PDP的情况以及他们的自付(OOP)药品支出。总体而言,我们发现PDP市场计划种类的减少降低了老年人参与PDP的可能性,而PDP市场集中度的提高增加了OOP药品支出。我们的主要结果对考虑了未观察到的个体层面异质性、地区特定时间趋势、保险公司的进入/退出以及基于准实验设计的替代识别方案的可能影响都是稳健的。此外,我们发现较年轻、更有优势、更健康的个体与较年老、较无优势、病情较重的个体相比,对行业整合的反应不同。前者更有可能根据PDP种类的减少调整他们的PDP参与,并且在PDP市场集中度增加时有更高的OOP药品支出。最后,我们发现,PDP种类的减少和PDP市场集中度的提高不仅直接影响PDP参与和OOP药品支出,这些变化还通过影响PDP特征间接影响医疗保险受益人。
原文链接:https://www.nber.org/papers/w32267